Marco Sacco

Dr. Marco Sacco

Università degli Studi di Torino, Turin, Piedmont, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
CRChiara Rosso
Chiara Rosso
KKKonstantin Kazankov
Konstantin Kazankov
RYRamy Younes
Ramy Younes
SESaeed Esmaili
Saeed Esmaili
MMMilena Marietti
Milena Marietti
EBElisabetta Bugianesi
Elisabetta Bugianesi

14 November 2017 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
ACAlessia Ciancio
Alessia Ciancio
RBRoberta Bosio
Roberta Bosio
SBSimona Bo
Simona Bo
MPMarianna Pellegrini
Marianna Pellegrini
Marco SaccoMarco Sacco
Marco Sacco
GSGiorgio Maria Saracco
Giorgio Maria Saracco

21 April 2022 in Endoscopy
Verified
Journal Article
Closed access
PDF file
Antonio FacciorussoAntonio Facciorusso
Antonio Facciorusso
BKBojan Kovacevic
Bojan Kovacevic
DYDennis Yang
Dennis Yang
FVFilipe Vilas-Boas
Filipe Vilas-Boas
BMBelén Martínez-Moreno
Belén Martínez-Moreno
SCStefano Francesco Crinò
Stefano Francesco Crinò
Background and study aims Endoscopic ultrasound-guided through-the-needle biopsy (TTNB) of pancreatic cystic lesions (PCLs) is associated with a non-negligible risk for adverse events (AEs). We aimed to identify the hierarchic interaction among independent predictors for TTNB-related AEs and to generate a prognostic model using recursive partitioning analysis (RPA). Patients and methods Multicenter retrospective analysis of 506 patients with PCLs who underwent TTNB. RPA of predictors for AEs was performed and the model was validated by means of bootstrap resampling. Results Mean cysts size was 36.7 mm. Most common diagnoses were intraductal papillary mucinous neoplasm (IPMN, 45 %), serous cystadenoma (18.8 %), and mucinous cystadenoma (12.8 %). Fifty-eight (11.5 %) AEs were observed. At multivariate analysis, age (odds ratio [OR] 1.32, 1.09–2.14; p = 0.05), number of TTNB passes (OR from 2.17, 1.32–4.34 to OR 3.16, 2.03–6.34 with the increase of the number of passes), complete aspiration of the cyst (OR 0.56, 0.31–0.95; p = 0.02), and diagnosis of IPMN (OR 4.16, 2.27–7.69; p < 0.001) were found to be independent predictors of AEs, as confirmed by logistic regression and random forest analyses. RPA identified three risk classes: high-risk (IPMN sampled with multiple microforceps passes, 28 % AEs rate), low-risk (1.4 % AE rate, including patients < 64 years with other-than-IPMN diagnosis sampled with ≤ 2 microforceps passes and with complete aspiration of the cyst) and middle-risk class (6.1 % AEs rate, including the remaining patients). Conclusion TTNB should be selectively used in the evaluation of patients with IPMN. The present model could be applied during patient selection as to optimize the benefit/risk of TTNB.

1 November 2015 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
WVWilma Debernardi Venon
Wilma Debernardi Venon
PPPaola Ponzo
Paola Ponzo
Marco SaccoMarco Sacco
Marco Sacco
GMGiulio Mengozzi
Giulio Mengozzi
SRSamuele Raso
Samuele Raso
AMAlfredo Marzano
Alfredo Marzano
The management of patients with liver cirrhosis undergoing invasive procedures is controversial and haemostasis assessment using routine laboratory is inappropriate. We evaluated the following: (a) the ability of thromboelastometry to predict the risk of bleeding in cirrhotic patients undergoing invasive procedures and enable a decision on the prophylactic transfusional strategy; (b) the contribution of platelet adhesion and aggregation tests in the assessment of haemostasis. Seventeen cirrhotic patients undergoing invasive procedures were analyzed retrospectively (training set). To obtain preliminary data, an observational study was carried out in 58 patients (test set). All 75 patients were evaluated by thromboelastometry. Platelet adhesion and aggregation were evaluated in 16 patients using Multiplate, PFA-100 and Light Transmission Aggregometry. Factor VIII was dosed in all patients of the test set. In the training set, thromboelastometry confirmed the haemostatic assessment shown by the conventional test only in 6/17 (35%) patients. In the test set, thromboelastometry identified all patients who had a bleeding event. In patients with a high risk of bleeding, the use of thromboelastometry was cost-effective, reducing the platelet infusions by 64%. Platelet adhesion/aggregation abnormalities were observed in 15/16 (94%) patients, but bleeding events occurred only in 2/15 (13%) patients. Thromboelastometry appears to be useful to screen cirrhotic patients undergoing invasive procedures to identify the risk of bleeding and to optimize the transfusional strategy. Adhesion/aggregation tests are not useful in identifying patients at risk of bleeding and their application is not cost-effective.

20 July 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
SMSilvia Martini
Silvia Martini
Marco SaccoMarco Sacco
Marco Sacco
SSSilvia Strona
Silvia Strona
DADaniele Arese
Daniele Arese
Francesco TandoiFrancesco Tandoi
Francesco Tandoi
RRRenato Romagnoli
Renato Romagnoli

1 September 2020 in Digestive and Liver Disease
Verified
Journal Article
Closed access
Davide Giuseppe RibaldoneDavide Giuseppe Ribaldone
Davide Giuseppe Ribaldone
MBMauro Bruno
Mauro Bruno
SGSilvia Gaia
Silvia Gaia
ACAlessandro Cantamessa
Alessandro Cantamessa
ABAlberto Bragoni
Alberto Bragoni
CAClaudio De Angelis
Claudio De Angelis